Industry

− If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to Prior Therapies1 − Positive Opinion Based on Phase 3 SOLSTICE Study Demonstrating Maribavir Was Statistically Superior to Conventional Therapies at Study Week 8, … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$QNCX–Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation at the Military Health System Research Symposium (MHSRS 2022), which took place September 12 to September 15, 2022, in Kissimmee, Florida. At MHSRS 2022, Quince presented a … [Read more…]

DALLAS–(BUSINESS WIRE)–Generational Equity, a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client, Greenleaf Growers, Inc. to 2900 Madison Ave Holdings, LLC (a holding company of Edible Garden, Inc.). The transaction closed September 2, 2022. Greenleaf Growers, located in Grand Rapids, Michigan, operates as a greenhouse … [Read more…]

— Updated Data from Phase 1 Danon Disease trial expected to include efficacy and safety data from pediatric cohort and longer-term data from adult cohort — — Company to webcast investor event on Sept. 30, at 8:00 a.m. ET — CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an … [Read more…]

– Positive Opinion Based on Landmark ZUMA-7 Study in Which 41% of Patients Demonstrated Event-Free Survival at Two Years versus 16% for Standard of Care – SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Eczema Therapeutics Market 2022-2026” report has been added to ResearchAndMarkets.com’s offering. The eczema therapeutics market is poised to grow by $4.36 bn during 2022-2026, accelerating at a CAGR of 9.6% during the forecast period. The report on the eczema therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, … [Read more…]

Ribbon-Cutting: Saturday, September 17 @ 10:00 a.m., Garden District NEW ORLEANS–(BUSINESS WIRE)–AIDS Healthcare Foundation (AHF), the largest, non-profit global AIDS organization, is pleased to announce that on Saturday, September 17, 2022, it is opening a new branch of its popular and award-winning Out of the Closet (OTC) thrift store—AHF’s first in Louisiana. The store site, … [Read more…]

— If Granted by the European Commission, Veklury Will Become the First and Only Authorized Antiviral Treatment for Pediatric Patients Under 12 Years of Age in the European Union — FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Dialysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global dialysis market reached a value of US$ 104.13 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 142.92 Billion by 2027, exhibiting a CAGR of … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Healthcare Fraud Analytics Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global healthcare fraud analytics market is expected to grow from $1.94 billion in 2021 to $2.43 billion in 2022 at a compound annual growth rate (CAGR) of 25.44%. The healthcare fraud analytics market is expected to reach $6.33 … [Read more…]